Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Operating Expenses (2019 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Other Operating Expenses for 7 consecutive years, with -$177000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to -$177000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $88.1 million, a 9399.03% increase, with the full-year FY2024 number at $3.0 million, up 7.65% from a year prior.
  • Other Operating Expenses was -$177000.0 for Q3 2025 at Whitehawk Therapeutics, down from $87.4 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $87.4 million in Q1 2025 to a low of -$177000.0 in Q3 2025.
  • A 5-year average of $15.3 million and a median of $676500.0 in 2023 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: tumbled 99.32% in 2022, then skyrocketed 317.57% in 2023.
  • Whitehawk Therapeutics' Other Operating Expenses stood at $87.3 million in 2021, then crashed by 99.75% to $222000.0 in 2022, then skyrocketed by 317.57% to $927000.0 in 2023, then dropped by 14.78% to $790000.0 in 2024, then plummeted by 122.41% to -$177000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Other Operating Expenses are -$177000.0 (Q3 2025), $87.4 million (Q1 2025), and $790000.0 (Q4 2024).